ClinicalTrials.gg
CompletedNCT00396266Updated Mar 7, 2014Results posted

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

A Phase 2 interventional study of G-CSF Plus Plerixafor in Multiple Myeloma and Lymphoma, Non-Hodgkin, sponsored by Genzyme, a Sanofi Company. Completed at 2 sites in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-07.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.

Enrollment
19th of 28
22 · median 38
Started
2005
with 4 others
Phase 2
17 of 28
none open now
Registered
8th of 28
by date
Lead sponsor
7 of 28
Genzyme, a Sanofi Company

Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 19th largest by enrollment, is one of 5 that started in 2005, is one of 17 in phase 2, and was the 8th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, or all of them as a file.
02

Study summary

This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Efficacy outcomes include evaluation of fold increase in circulating CD34+ cells from just before the first plerixafor injection to 10-11 hours post plerixafor (just before apheresis) and assessment of successful polymorphonuclear leukocyte (PMN) engraftment after transplantation. Data from this protocol will assist in the determination of the dosing schedule for future studies.

Read the detailed description

Participants with NHL and MM who have undergone prior cyto-reductive chemotherapy, are to be autologously transplanted, and meet the inclusion/exclusion criteria are eligible to enter the study. The only change to the standard of care is the addition of plerixafor to a granulocyte colony-stimulating factor (G-CSF) mobilization regimen on the day prior to apheresis. Participants will undergo mobilization with G-CSF (10 mcg/kg each day) and will receive plerixafor (240 mcg/kg) in the evening prior to apheresis. Participants will undergo apheresis for up to 5 consecutive days in order to collect the target number of CD34+ stem cells (≥ 5*10\^6 CD34+ cells/kg for either single or tandem transplant). After apheresis, all participants will be treated with high-dose chemotherapy in preparation for transplantation. Participants will be transplanted with cells obtained from the G-CSF and plerixafor mobilization regimen. The increase in CD34+ cells in the peripheral blood from the time of the plerixafor dose to just prior to apheresis and the number of CD34+ cells in the apheresis product will be measured. Success of the transplantation(s) will be evaluated by the time to engraftment of polymorphonuclear leukocytes (PMN). A subpopulation will have pharmacokinetic and pharmacodynamic analysis done.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Multiple Myeloma
  • Lymphoma, Non-Hodgkin

Keywords

  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • stem cell mobilization
  • AMD3100
  • autologous transplantation
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of non-Hodgkin's lymphoma (NHL) or multiple myoloma (MM) eligible for transplantation
  • No more than 3 prior regimens of chemotherapy
  • More than 4 weeks since last cycle of chemotherapy. Patient recovered from all acute toxic effects of prior chemotherapy.
  • (ECOG) performance status of 0 or 1
  • White blood cell (WBC) count >3.0*10\^9/L
  • Absolute polymorphonuclear cells (PMN) count >1.5*10\^9/L
  • (PLT) count >100*10\^9/L
  • Serum creatinine \<=2.2 mg/dL
  • Serum glutamic oxaloacetic transaminase (), serum glutamic pyruvic transaminase (SGPT) and total \<2 x (ULN)
  • Left ventricle >45% by normal echocardiogram or multiple-gated acquisition (MUGA) scan
  • Forced expiratory volume of the lung in the first second () >60% of predicted or diffusing capacity of the lung for carbon monoxide (DLCO) >45% of predicted
  • Negative for (HIV) type 1
  • Women of child bearing potential agreed to use an approved form of .

Exclusion criteria

Exclusion Criteria:

    • Patients who have failed previous collections

      • or carcinomatous meningitis
      • History of ventricular arrhythmias
      • A co-morbid condition which, in the view of the investigator, renders the patient at high risk for treatment complications
      • A residual acute medical condition resulting from prior chemotherapy
      • Acute infection
      • Fever (temp >38°C/100.4°F)
      • Patients whose actual body weight exceeds 150% of their ideal body weight
      • History of paresthesias (at least Grade 2)
      • Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization period
      • Positive pregnancy test in female patients
      • Lactating females
      • Patients of unwilling to implement adequate .
      • Patients who have deterioration of their clinical status or laboratory parameters between the time of enrolment and transplant (such that they no longer meet entry criteria) may be removed from study at the discretion of the treating physician, principal investigator, or sponsor.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Non-Hodgkin's Lymphoma (NHL)

    Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Drug: G-CSF Plus Plerixafor

  • Experimental
    Multiple Myeloma (MM)

    Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Drug: G-CSF Plus Plerixafor

Interventions

  • DrugG-CSF Plus Plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Also known as: Mozobil, AMD3100

06

What researchers measure

Primary outcomes

  1. Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)

    Number of participants with treatment emergent adverse events (TEAEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').

    Time frame: Day 1 to approximately Day 38 (before start of chemotherapy)

Secondary outcomes

  1. Number of Participants Who Had a ≥ 2-fold Increase in Circulating CD34+ Cells

    To determine if NHL and MM patients mobilized with G-CSF (10 µg/kg QD) plus plerixafor will have a ≥2-fold increase in circulating CD34+ cells from time 0 to 11 hours after a dose of plerixafor.

    Time frame: Time 0 to 11 hours after the first dose of plerixafor

  2. Number of Transplants Resulting In Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post-Transplant

    Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

    Time frame: 2 months

  3. Tumor Cell Mobilization in Non-Hodgkin's Lymphoma (NHL) Participants Following Plerixafor Treatment

    In a subpopulation of NHL participants, the mobilization of NHL cells was to be evaluated. None of the samples were analyzed due to sample degradation.

    Time frame: Prior to the first (Day 4) and last dose of plerixafor, immediately prior to each apheresis, and 24 hours after the last apheresis.

  4. Single-dose Maximum Observed Concentration of Plerixafor (Cmax)

    Evaluation of Cmax following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Cmax was determined from direct observation of the data.

    Time frame: Day 5 - 0 to 10 hours post-first plerixafor dose.

  5. Single-dose Time to Maximum Concentration of Plerixafor (Tmax)

    Evaluation of Tmax following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Tmax was determined from direct observation of the data.

    Time frame: Day 5 - 0 to 10 hours post-first plerixafor dose

  6. Single-dose Half-life of Plerixafor (T1/2)

    Evaluation of T1/2 following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. T1/2 was determined from non-compartmental analysis.

    Time frame: Day 5 - 0 to 10 hours post-first plerixafor dose.

  7. Single-dose Area Under the Concentration-time Curve of Plerixafor From Time 0 to 10 Hours Post-dose (AUC0-10)

    Evaluation of AUC0-10 following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. AUC0-10 was determined from non-compartmental analysis.

    Time frame: Day 5 - 0 to 10 hours post-first plerixafor dose.

  8. Single-dose Apparent Clearance of Plerixafor (CL/F)

    Evaluation of Cl/F following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Cl/F was determined from non-compartmental analysis.

    Time frame: Day 5 - 0 to 10 hours post-first plerixafor dose.

  9. Single-dose Apparent Volume of Distribution of Plerixafor (Vz/F) in NHL and MM Patients

    Evaluation of Vz/F following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Vz/F was determined from non-compartmental analysis.

    Time frame: Day 5 - 0 to 10 hours post-first plerixafor dose.

  10. Maximum Fold Increase in Peripheral Blood CD34+ Cells From Baseline Following Initial Administration of Plerixafor

    A pharmacodynamic evaluation to determine the maximum fold increase in peripheral blood CD34+ cells following the initial administration of plerixafor by measuring the fold increase at time points up to 10 hours post plerixafor relative to baseline (immediately prior to plerixafor).

    Time frame: Day 4 (10 hours post first plerixafor dose)

07

Results

Posted Nov 25, 2010

Participant flow

Participant flow — Overall Study
MilestoneNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
Started814
Completed814
Not completed00

Outcome measures

SecondaryNumber of Participants Who Had a ≥ 2-fold Increase in Circulating CD34+ Cells

To determine if NHL and MM patients mobilized with G-CSF (10 µg/kg QD) plus plerixafor will have a ≥2-fold increase in circulating CD34+ cells from time 0 to 11 hours after a dose of plerixafor.

Time frame:
Time 0 to 11 hours after the first dose of plerixafor
Reported as:
Number · participants
Number of Participants Who Had a ≥ 2-fold Increase in Circulating CD34+ Cells
participantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
≥ 2-fold Increase81321
< 2-fold Increase000
SecondaryNumber of Transplants Resulting In Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post-Transplant

Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

Time frame:
2 months
Reported as:
Number · number of transplants
Number of Transplants Resulting In Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post-Transplant
number of transplantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
≤ Day 127 ± 1.510 ± 2.817
Day 13 to Day 21156
≥ Day 22000
SecondaryTumor Cell Mobilization in Non-Hodgkin's Lymphoma (NHL) Participants Following Plerixafor Treatment

In a subpopulation of NHL participants, the mobilization of NHL cells was to be evaluated. None of the samples were analyzed due to sample degradation.

Time frame:
Prior to the first (Day 4) and last dose of plerixafor, immediately prior to each apheresis, and 24 hours after the last apheresis.

No measurements were reported for this outcome.

SecondarySingle-dose Maximum Observed Concentration of Plerixafor (Cmax)

Evaluation of Cmax following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Cmax was determined from direct observation of the data.

Time frame:
Day 5 - 0 to 10 hours post-first plerixafor dose.
Reported as:
Mean · ng/mL
Single-dose Maximum Observed Concentration of Plerixafor (Cmax)
ng/mLPK Subgroup
Single-dose Maximum Observed Concentration of Plerixafor (Cmax)926 ± 237
SecondarySingle-dose Time to Maximum Concentration of Plerixafor (Tmax)

Evaluation of Tmax following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Tmax was determined from direct observation of the data.

Time frame:
Day 5 - 0 to 10 hours post-first plerixafor dose
Reported as:
Median · hours
Single-dose Time to Maximum Concentration of Plerixafor (Tmax)
hoursPK Subgroup
Single-dose Time to Maximum Concentration of Plerixafor (Tmax)0.5 ± 0.2
SecondarySingle-dose Half-life of Plerixafor (T1/2)

Evaluation of T1/2 following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. T1/2 was determined from non-compartmental analysis.

Time frame:
Day 5 - 0 to 10 hours post-first plerixafor dose.
Reported as:
Mean · hours
Single-dose Half-life of Plerixafor (T1/2)
hoursPK Subgroup
Single-dose Half-life of Plerixafor (T1/2)5.1 ± 2.2
SecondarySingle-dose Area Under the Concentration-time Curve of Plerixafor From Time 0 to 10 Hours Post-dose (AUC0-10)

Evaluation of AUC0-10 following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. AUC0-10 was determined from non-compartmental analysis.

Time frame:
Day 5 - 0 to 10 hours post-first plerixafor dose.
Reported as:
Mean · ng•h/mL
Single-dose Area Under the Concentration-time Curve of Plerixafor From Time 0 to 10 Hours Post-dose (AUC0-10)
ng•h/mLPK Subgroup
Single-dose Area Under the Concentration-time Curve of Plerixafor From Time 0 to 10 Hours Post-dose (AUC0-10)3594 ± 697
SecondarySingle-dose Apparent Clearance of Plerixafor (CL/F)

Evaluation of Cl/F following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Cl/F was determined from non-compartmental analysis.

Time frame:
Day 5 - 0 to 10 hours post-first plerixafor dose.
Reported as:
Mean · mL/hour
Single-dose Apparent Clearance of Plerixafor (CL/F)
mL/hourPK Subgroup
Single-dose Apparent Clearance of Plerixafor (CL/F)4767 ± 1063
PrimaryNumber of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)

Number of participants with treatment emergent adverse events (TEAEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').

Time frame:
Day 1 to approximately Day 38 (before start of chemotherapy)
Reported as:
Number · participants
Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)
participantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
AE Severity (Mild)4812
AE Severity (Moderate)4610
AE Severity (Severe)000
AE Relationship to Drug (Not related)000
AE Relationship to Drug (Probably not related)235
AE Relationship to Drug (Possibly related)055
AE Relationship to Drug(Probably related)459
AE Relationship to Drug (Definitely related)213
SecondarySingle-dose Apparent Volume of Distribution of Plerixafor (Vz/F) in NHL and MM Patients

Evaluation of Vz/F following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Vz/F was determined from non-compartmental analysis.

Time frame:
Day 5 - 0 to 10 hours post-first plerixafor dose.
Reported as:
Mean · mL
Single-dose Apparent Volume of Distribution of Plerixafor (Vz/F) in NHL and MM Patients
mLPK Subgroup
Single-dose Apparent Volume of Distribution of Plerixafor (Vz/F) in NHL and MM Patients33668 ± 10531
SecondaryMaximum Fold Increase in Peripheral Blood CD34+ Cells From Baseline Following Initial Administration of Plerixafor

A pharmacodynamic evaluation to determine the maximum fold increase in peripheral blood CD34+ cells following the initial administration of plerixafor by measuring the fold increase at time points up to 10 hours post plerixafor relative to baseline (immediately prior to plerixafor).

Time frame:
Day 4 (10 hours post first plerixafor dose)
Reported as:
Median · ratio
Maximum Fold Increase in Peripheral Blood CD34+ Cells From Baseline Following Initial Administration of Plerixafor
ratioPD Subgroup
Maximum Fold Increase in Peripheral Blood CD34+ Cells From Baseline Following Initial Administration of Plerixafor4.2 (3.0 to 5.5)

Adverse events

Collected over Treatment emergent AEs covering Day 1 (start of G-CSF Mobilization to the day before starting chemotherapy (approximately Day 38).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-Hodgkin's Lymphoma (NHL)—1/8 (12.5%)8/8 (100%)
Multiple Myeloma (MM)—2/14 (14.3%)14/14 (100%)
Most frequent serious events
Most frequent serious events
EventNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
Catheter site haemorrhageGeneral disorders1/81/14
Catheter site painGeneral disorders0/81/14
Catheter bacteraemiaInfections and infestations0/81/14
Most frequent other events
Showing 10 of 74
Most frequent other events
EventNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
DiarrhoeaGastrointestinal disorders1/87/14
Injection site erythemaGeneral disorders4/86/14
Back painMusculoskeletal and connective tissue disorders4/82/14
ParaesthesiaNervous system disorders4/81/14
Catheter site erythemaGeneral disorders1/86/14
FatigueGeneral disorders3/86/14
Bone painMusculoskeletal and connective tissue disorders1/86/14
NauseaGastrointestinal disorders3/84/14
HeadacheNervous system disorders3/81/14
Catheter site painGeneral disorders2/83/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Mean57.9 ± 8.757.5 ± 10.357.6 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Female347
Male51015
08

Study locations

2 sites
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 4N2, Canada
  • Vancouver General Hospital, BC Cancer Agency
    Vancouver, British Columbia V5Z 4E3, Canada
09

References and documents

Publications

  • Stewart DA, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018. PubMed 19135941 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Jan 2005
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Nov 25, 2010
Last update
Mar 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396266
First posted
Nov 6, 2006
Start date
Jan 2005
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Nov 25, 2010
Last update
Mar 7, 2014

Study contacts

Medical Monitor, MD
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion